drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00108 | DB12267 | 1,066 | 1,476 | [
"DDInter1268",
"DDInter233"
] | Natalizumab | Brigatinib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1066,
25,
1476
]
],
[
[
1066,
25,
168
],
[
168,
23,
1476
]
],
[
[
1066,
25,
629
],
[
629,
24,
1476
]
],
[
[
1066,
64,
1184
],
[
1184,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u}... | Natalizumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate intera... |
DB09034 | DB12500 | 1,313 | 283 | [
"DDInter1733",
"DDInter714"
] | Suvorexant | Fedratinib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1313,
25,
283
]
],
[
[
1313,
25,
351
],
[
351,
23,
283
]
],
[
[
1313,
64,
1593
],
[
1593,
23,
283
]
],
[
[
1313,
64,
1419
],
[
1419,
... | [
[
[
"Suvorexant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Suvorexant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} m... | Suvorexant may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Suvorexant may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interacti... |
DB00673 | DB11652 | 723 | 1,155 | [
"DDInter112",
"DDInter1891"
] | Aprepitant | Tucatinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
723,
24,
1155
]
],
[
[
723,
23,
222
],
[
222,
23,
1155
]
],
[
[
723,
62,
1101
],
[
1101,
23,
1155
]
],
[
[
723,
63,
1424
],
[
1424,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene ... |
DB00086 | DB11312 | 1,167 | 298 | [
"DDInter1712",
"DDInter1542"
] | Streptokinase | Protein C | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the e... | Moderate | 1 | [
[
[
1167,
24,
298
]
],
[
[
1167,
25,
500
],
[
500,
24,
298
]
],
[
[
1167,
64,
834
],
[
834,
24,
298
]
],
[
[
1167,
25,
1421
],
[
1421,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxa... | Streptokinase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Streptokinase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may caus... |
DB00820 | DB08865 | 402 | 1,593 | [
"DDInter1736",
"DDInter448"
] | Tadalafil | Crizotinib | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
402,
24,
1593
]
],
[
[
402,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
402,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
402,
24,
283
],
[
283,
... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Tadalafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tadalafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Tadalafil (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib ... |
DB00398 | DB15982 | 79 | 1,339 | [
"DDInter1702",
"DDInter193"
] | Sorafenib | Berotralstat | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
79,
25,
1339
]
],
[
[
79,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
79,
24,
1213
],
[
1213,
24,
1339
]
],
[
[
79,
25,
351
],
[
351,
... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib... |
DB00736 | DB01082 | 660 | 1,448 | [
"DDInter676",
"DDInter1713"
] | Esomeprazole | Streptomycin | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
660,
24,
1448
]
],
[
[
660,
21,
29327
],
[
29327,
60,
1448
]
],
[
[
660,
24,
361
],
[
361,
24,
1448
]
],
[
[
660,
1,
1215
],
[
1215,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Esomeprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Renal failure"
],
[
"Renal failure",
"{u} (Side E... | Esomeprazole (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Streptomycin (Compound)
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00741 | DB01144 | 167 | 1,326 | [
"DDInter885",
"DDInter540"
] | Hydrocortisone | Diclofenamide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
167,
24,
1326
]
],
[
[
167,
24,
504
],
[
504,
1,
1326
]
],
[
[
167,
24,
359
],
[
359,
40,
1326
]
],
[
[
167,
21,
29090
],
[
29090,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiaz... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compo... |
DB01125 | DB01156 | 279 | 593 | [
"DDInter98",
"DDInter252"
] | Anisindione | Bupropion | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
279,
24,
593
]
],
[
[
279,
25,
256
],
[
256,
62,
593
]
],
[
[
279,
63,
752
],
[
752,
23,
593
]
],
[
[
279,
24,
1532
],
[
1532,
6... | [
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel"... | Anisindione may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Bupropion
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a m... |
DB00026 | DB10343 | 1,184 | 962 | [
"DDInter94",
"DDInter160"
] | Anakinra | Bacillus calmette-guerin substrain tice live antigen | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1184,
25,
962
]
],
[
[
1184,
24,
617
],
[
617,
24,
962
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1184,
24,
1342
],
[
1342,
... | [
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bude... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Anakinra may lead to a major life threatening interaction when taken wit... |
DB01125 | DB08816 | 279 | 578 | [
"DDInter98",
"DDInter1802"
] | Anisindione | Ticagrelor | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
279,
24,
578
]
],
[
[
279,
64,
1578
],
[
1578,
24,
578
]
],
[
[
279,
63,
723
],
[
723,
24,
578
]
],
[
[
279,
24,
1220
],
[
1220,
... | [
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin... | Anisindione may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause ... |
DB01263 | DB09065 | 859 | 760 | [
"DDInter1494",
"DDInter424"
] | Posaconazole | Cobicistat | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
859,
24,
760
]
],
[
[
859,
62,
1101
],
[
1101,
23,
760
]
],
[
[
859,
24,
1374
],
[
1374,
23,
760
]
],
[
[
859,
63,
1041
],
[
1041,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Posaconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abira... |
DB00495 | DB00741 | 139 | 167 | [
"DDInter1961",
"DDInter885"
] | Zidovudine | Hydrocortisone | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
139,
24,
167
]
],
[
[
139,
24,
1220
],
[
1220,
40,
167
]
],
[
[
139,
24,
870
],
[
870,
1,
167
]
],
[
[
139,
63,
251
],
[
251,
40... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hy... |
DB00570 | DB01098 | 147 | 14 | [
"DDInter1936",
"DDInter1622"
] | Vinblastine | Rosuvastatin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
147,
24,
14
]
],
[
[
147,
24,
671
],
[
671,
24,
14
]
],
[
[
147,
6,
10417
],
[
10417,
45,
14
]
],
[
[
147,
7,
1860
],
[
1860,
46... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Vinblastine (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Rosuvastatin (Compound)
Vinblastine ... |
DB01229 | DB10315 | 973 | 1,137 | [
"DDInter1377",
"DDInter1127"
] | Paclitaxel | Measles virus vaccine live attenuated | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
973,
25,
1137
]
],
[
[
973,
64,
581
],
[
581,
25,
1137
]
],
[
[
973,
24,
384
],
[
384,
25,
1137
]
],
[
[
973,
63,
1101
],
[
1101,
... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Paclitaxel may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisi... |
DB00285 | DB01225 | 1,100 | 500 | [
"DDInter1927",
"DDInter645"
] | Venlafaxine | Enoxaparin | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
1100,
24,
500
]
],
[
[
1100,
21,
28804
],
[
28804,
60,
500
]
],
[
[
1100,
25,
1039
],
[
1039,
24,
500
]
],
[
[
1100,
1,
643
],
[
643,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) causes {v} (Side Effect)",
"Purpura"
],
[
"Purpura",
"{u} (Side Effect) is caused... | Venlafaxine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Enoxaparin (Compound)
Venlafaxine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Ven... |
DB00927 | DB09330 | 1,559 | 985 | [
"DDInter712",
"DDInter1352"
] | Famotidine | Osimertinib | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1559,
24,
985
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
985
]
],
[
[
1559,
62,
112
],
[
112,
23,
985
]
],
[
[
1559,
24,
480
],
[
480,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole ... |
DB00472 | DB09564 | 758 | 1,296 | [
"DDInter758",
"DDInter930"
] | Fluoxetine | Insulin degludec | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
758,
24,
1296
]
],
[
[
758,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
758,
62,
542
],
[
542,
24,
1296
]
],
[
[
758,
64,
73
],
[
73,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine a... |
DB00332 | DB01019 | 1,089 | 427 | [
"DDInter970",
"DDInter199"
] | Ipratropium | Bethanechol | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For exampl... | Moderate | 1 | [
[
[
1089,
24,
427
]
],
[
[
1089,
6,
2720
],
[
2720,
45,
427
]
],
[
[
1089,
21,
29316
],
[
29316,
60,
427
]
],
[
[
1089,
24,
1442
],
[
1442... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bethanechol"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)"... | Ipratropium (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Bethanechol (Compound)
Ipratropium (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Bethanechol (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Sc... |
DB00773 | DB11652 | 896 | 1,155 | [
"DDInter702",
"DDInter1891"
] | Etoposide | Tucatinib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
896,
24,
1155
]
],
[
[
896,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
896,
63,
522
],
[
522,
24,
1155
]
],
[
[
896,
24,
309
],
[
309,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukas... |
DB06772 | DB14783 | 310 | 287 | [
"DDInter259",
"DDInter574"
] | Cabazitaxel | Diroximel fumarate | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
310,
24,
287
]
],
[
[
310,
63,
1101
],
[
1101,
24,
287
]
],
[
[
310,
24,
384
],
[
384,
24,
287
]
],
[
[
310,
25,
1510
],
[
1510,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib ... |
DB00692 | DB00962 | 274 | 1,639 | [
"DDInter1448",
"DDInter1957"
] | Phentolamine | Zaleplon | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
274,
24,
1639
]
],
[
[
274,
21,
29196
],
[
29196,
60,
1639
]
],
[
[
274,
63,
530
],
[
530,
24,
1639
]
],
[
[
274,
24,
1264
],
[
1264,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect)... | Phentolamine (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Zaleplon (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with... |
DB06595 | DB11853 | 1,491 | 230 | [
"DDInter1214",
"DDInter1577"
] | Midostaurin | Relugolix | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
1491,
24,
230
]
],
[
[
1491,
25,
129
],
[
129,
23,
230
]
],
[
[
1491,
24,
1094
],
[
1094,
23,
230
]
],
[
[
1491,
62,
112
],
[
112,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalut... | Midostaurin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may c... |
DB00736 | DB01045 | 660 | 463 | [
"DDInter676",
"DDInter1590"
] | Esomeprazole | Rifampicin | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
660,
24,
463
]
],
[
[
660,
6,
10215
],
[
10215,
45,
463
]
],
[
[
660,
63,
542
],
[
542,
24,
463
]
],
[
[
660,
24,
187
],
[
187,
... | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Esomeprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compo... | Esomeprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rifampicin (Compound)
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Esomep... |
DB00574 | DB00814 | 121 | 1,171 | [
"DDInter717",
"DDInter1143"
] | Fenfluramine | Meloxicam | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
121,
24,
1171
]
],
[
[
121,
63,
1027
],
[
1027,
40,
1171
]
],
[
[
121,
24,
936
],
[
936,
63,
1171
]
],
[
[
121,
63,
366
],
[
366,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor and Cangrelor may cause a moderate interaction that could ... |
DB00446 | DB01326 | 597 | 1,124 | [
"DDInter351",
"DDInter312"
] | Chloramphenicol | Cefamandole | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. It is no longer marketed in the United States. | Moderate | 1 | [
[
[
597,
24,
1124
]
],
[
[
597,
24,
1305
],
[
1305,
1,
1124
]
],
[
[
597,
24,
665
],
[
665,
40,
1124
]
],
[
[
597,
63,
277
],
[
277,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefaclor"
],... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefaclor and Cefaclor (Compound) resembles Cefamandole (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefamandole (Co... |
DB00662 | DB01121 | 717 | 94 | [
"DDInter1873",
"DDInter1437"
] | Trimethobenzamide | Phenacemide | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures. | Moderate | 1 | [
[
[
717,
24,
94
]
],
[
[
717,
24,
551
],
[
551,
1,
94
]
],
[
[
717,
63,
1614
],
[
1614,
24,
94
]
],
[
[
717,
24,
662
],
[
662,
24,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Phenacemide (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction... |
DB00258 | DB00365 | 666 | 839 | [
"DDInter270",
"DDInter842"
] | Calcium acetate | Grepafloxacin | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Moderate | 1 | [
[
[
666,
24,
839
]
],
[
[
666,
21,
28658
],
[
28658,
60,
1487
],
[
1487,
64,
839
]
],
[
[
666,
21,
29162
],
[
29162,
60,
663
],
[
663,
6... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Calcium acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effe... | Calcium acetate (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound) and Hydroxychloroquine may lead to a major life threatening interaction when taken with Grepafloxacin
Calcium acetate (Compound) causes Stupor (Side Effect) and Stupor (Side Effect) is caused b... |
DB00023 | DB01132 | 305 | 1,130 | [
"DDInter127",
"DDInter1472"
] | Asparaginase Escherichia coli | Pioglitazone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
305,
24,
1130
]
],
[
[
305,
24,
566
],
[
566,
23,
1130
]
],
[
[
305,
24,
517
],
[
517,
62,
1130
]
],
[
[
305,
24,
242
],
[
242,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate ... |
DB00741 | DB15699 | 167 | 652 | [
"DDInter885",
"DDInter232"
] | Hydrocortisone | Brexucabtagene autoleucel | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
167,
25,
652
]
],
[
[
167,
24,
259
],
[
259,
24,
652
]
],
[
[
167,
63,
1184
],
[
1184,
24,
652
]
],
[
[
167,
25,
976
],
[
976,
2... | [
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00242 | DB11569 | 1,064 | 1,093 | [
"DDInter392",
"DDInter1003"
] | Cladribine | Ixekizumab | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Major | 2 | [
[
[
1064,
25,
1093
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
1093
]
],
[
[
1064,
64,
66
],
[
66,
24,
1093
]
],
[
[
1064,
24,
496
],
[
496,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Cladribine may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a mo... |
DB06589 | DB06674 | 1,250 | 908 | [
"DDInter1400",
"DDInter837"
] | Pazopanib | Golimumab | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1250,
25,
908
]
],
[
[
1250,
63,
336
],
[
336,
24,
908
]
],
[
[
1250,
64,
828
],
[
828,
24,
908
]
],
[
[
1250,
24,
200
],
[
200,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Pazopanib may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may cause a mod... |
DB00353 | DB00400 | 588 | 353 | [
"DDInter1187",
"DDInter843"
] | Methylergometrine | Griseofulvin | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Moderate | 1 | [
[
[
588,
24,
353
]
],
[
[
588,
6,
8374
],
[
8374,
45,
353
]
],
[
[
588,
21,
28722
],
[
28722,
60,
353
]
],
[
[
588,
63,
1101
],
[
1101,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by ... | Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Methylergometrine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Griseofulvin (Compound)
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00489 | DB04868 | 17 | 478 | [
"DDInter1704",
"DDInter1293"
] | Sotalol | Nilotinib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
17,
25,
478
]
],
[
[
17,
6,
3576
],
[
3576,
46,
478
]
],
[
[
17,
21,
28963
],
[
28963,
60,
478
]
],
[
[
17,
23,
112
],
[
112,
23... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Sotalol",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"... | Sotalol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Nilotinib (Compound)
Sotalol (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole ... |
DB01269 | DB09054 | 38 | 384 | [
"DDInter1386",
"DDInter905"
] | Panitumumab | Idelalisib | Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
38,
24,
384
]
],
[
[
38,
63,
1555
],
[
1555,
24,
384
]
],
[
[
38,
64,
228
],
[
228,
24,
384
]
],
[
[
38,
64,
1568
],
[
1568,
25,... | [
[
[
"Panitumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Panitumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[... | Panitumumab may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Panitumumab may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may ca... |
DB00176 | DB01166 | 529 | 477 | [
"DDInter770",
"DDInter379"
] | Fluvoxamine | Cilostazol | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
529,
25,
477
]
],
[
[
529,
6,
8374
],
[
8374,
45,
477
]
],
[
[
529,
21,
28919
],
[
28919,
60,
477
]
],
[
[
529,
24,
126
],
[
126,
... | [
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilos... | Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Fluvoxamine (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and War... |
DB00396 | DB06655 | 989 | 5 | [
"DDInter1529",
"DDInter1077"
] | Progesterone | Liraglutide | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
989,
24,
5
]
],
[
[
989,
24,
353
],
[
353,
23,
5
]
],
[
[
989,
40,
870
],
[
870,
24,
5
]
],
[
[
989,
63,
245
],
[
245,
24,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Progesterone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate inter... |
DB01591 | DB13074 | 667 | 877 | [
"DDInter1696",
"DDInter1110"
] | Solifenacin | Macimorelin | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
667,
25,
877
]
],
[
[
667,
62,
112
],
[
112,
23,
877
]
],
[
[
667,
24,
1320
],
[
1320,
24,
877
]
],
[
[
667,
63,
85
],
[
85,
24,... | [
[
[
"Solifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Solifenacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Ela... |
DB00384 | DB00741 | 1,275 | 167 | [
"DDInter1859",
"DDInter885"
] | Triamterene | Hydrocortisone | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1275,
24,
167
]
],
[
[
1275,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1275,
24,
870
],
[
870,
1,
167
]
],
[
[
1275,
21,
28680
],
[
28680,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles ... |
DB00794 | DB09049 | 759 | 1,135 | [
"DDInter1521",
"DDInter1261"
] | Primidone | Naloxegol | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
759,
25,
1135
]
],
[
[
759,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
759,
24,
971
],
[
971,
62,
1135
]
],
[
[
759,
63,
1424
],
[
1424,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may ca... | Primidone may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a m... |
DB01035 | DB09080 | 1,401 | 144 | [
"DDInter1524",
"DDInter1331"
] | Procainamide | Olodaterol | A derivative of procaine with less CNS action. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1401,
24,
144
]
],
[
[
1401,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1401,
64,
11
],
[
11,
24,
144
]
],
[
[
1401,
63,
543
],
[
543,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingol... | Procainamide may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Procainamide may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate ... |
DB00514 | DB01037 | 506 | 1,161 | [
"DDInter527",
"DDInter1653"
] | Dextromethorphan | Selegiline | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Major | 2 | [
[
[
506,
25,
1161
]
],
[
[
506,
25,
551
],
[
551,
1,
1161
]
],
[
[
506,
24,
1529
],
[
1529,
1,
1161
]
],
[
[
506,
63,
80
],
[
80,
40... | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
... | Dextromethorphan may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Selegiline (Compoun... |
DB01242 | DB09078 | 1,237 | 1,228 | [
"DDInter410",
"DDInter1036"
] | Clomipramine | Lenvatinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1237,
24,
1228
]
],
[
[
1237,
62,
112
],
[
112,
23,
1228
]
],
[
[
1237,
63,
609
],
[
609,
24,
1228
]
],
[
[
1237,
74,
1264
],
[
1264,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Clomipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin ... |
DB01058 | DB08912 | 978 | 1,040 | [
"DDInter1510",
"DDInter462"
] | Praziquantel | Dabrafenib | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
978,
24,
1040
]
],
[
[
978,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
978,
7,
13128
],
[
13128,
46,
1040
]
],
[
[
978,
21,
28900
],
[
28900... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Praziquantel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Praziquantel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Praziquantel (Compound) upregulates NARFL (Gene) and NARFL (Gene) is upregulated by Dabrafenib (Compound)
Praziquantel (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (... |
DB09083 | DB09330 | 880 | 985 | [
"DDInter996",
"DDInter1352"
] | Ivabradine | Osimertinib | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
880,
25,
985
]
],
[
[
880,
63,
1478
],
[
1478,
24,
985
]
],
[
[
880,
64,
1181
],
[
1181,
24,
985
]
],
[
[
880,
25,
283
],
[
283,
... | [
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor"... | Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ivabradine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause... |
DB00056 | DB09122 | 816 | 1,613 | [
"DDInter814",
"DDInter1409"
] | Gemtuzumab ozogamicin | Peginterferon beta-1a | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
816,
24,
1613
]
],
[
[
816,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
816,
23,
1176
],
[
1176,
24,
1613
]
],
[
[
816,
24,
287
],
[
287,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when... |
DB01033 | DB01101 | 328 | 60 | [
"DDInter1156",
"DDInter285"
] | Mercaptopurine | Capecitabine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
328,
24,
60
]
],
[
[
328,
21,
28799
],
[
28799,
60,
60
]
],
[
[
328,
23,
872
],
[
872,
62,
60
]
],
[
[
328,
62,
1176
],
[
1176,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Mercaptopurine",
"{u} (Compound) causes {v} (Side Effect)",
"Neoplasm"
],
[
"Neoplasm",
"{u} (Side Effect)... | Mercaptopurine (Compound) causes Neoplasm (Side Effect) and Neoplasm (Side Effect) is caused by Capecitabine (Compound)
Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with... |
DB04868 | DB04908 | 478 | 1,671 | [
"DDInter1293",
"DDInter741"
] | Nilotinib | Flibanserin | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
478,
24,
1671
]
],
[
[
478,
23,
1135
],
[
1135,
62,
1671
]
],
[
[
478,
63,
168
],
[
168,
23,
1671
]
],
[
[
478,
24,
741
],
[
741,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib ma... |
DB00040 | DB09351 | 27 | 722 | [
"DDInter827",
"DDInter1048"
] | Glucagon | Levobetaxolol (ophthalmic) | Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and... | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. | Minor | 0 | [
[
[
27,
23,
722
]
],
[
[
27,
23,
819
],
[
819,
24,
1276
],
[
1276,
63,
722
]
],
[
[
27,
23,
819
],
[
819,
24,
1593
],
[
1593,
24,
... | [
[
[
"Glucagon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Glucagon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
"... | Glucagon may cause a minor interaction that can limit clinical effects when taken with Levobetaxolol
Glucagon may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib ma... |
DB00264 | DB00782 | 88 | 1,123 | [
"DDInter1200",
"DDInter1535"
] | Metoprolol | Propantheline | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
88,
24,
1123
]
],
[
[
88,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
88,
40,
17
],
[
17,
24,
1123
]
],
[
[
88,
24,
1192
],
[
1192,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Metoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect... | Metoprolol (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Metoprolol (Compound) resembles Sotalol (Compound) and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Metoprolol may cause a moderate intera... |
DB00673 | DB01095 | 723 | 671 | [
"DDInter112",
"DDInter769"
] | Aprepitant | Fluvastatin | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
723,
24,
671
]
],
[
[
723,
24,
700
],
[
700,
40,
671
]
],
[
[
723,
6,
7950
],
[
7950,
45,
671
]
],
[
[
723,
21,
29291
],
[
29291,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Fluvastatin (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Fluvastatin (Compound)
Aprepitant (Compound) causes Muscular weakness (Side Effect)... |
DB01126 | DB11901 | 1,260 | 913 | [
"DDInter611",
"DDInter107"
] | Dutasteride | Apalutamide | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1260,
24,
913
]
],
[
[
1260,
63,
600
],
[
600,
24,
913
]
],
[
[
1260,
24,
609
],
[
609,
24,
913
]
],
[
[
1260,
24,
1619
],
[
1619,
... | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
... | Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB06616 | DB14730 | 594 | 1,412 | [
"DDInter224",
"DDInter264"
] | Bosutinib | Calaspargase pegol | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
594,
24,
1412
]
],
[
[
594,
24,
159
],
[
159,
24,
1412
]
],
[
[
594,
40,
883
],
[
883,
24,
1412
]
],
[
[
594,
25,
868
],
[
868,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Bosutinib (Compound) resembles Gefitinib (Compound) and Gefitinib may cause a moderate interaction ... |
DB00009 | DB08901 | 1,271 | 1,468 | [
"DDInter56",
"DDInter1492"
] | Alteplase | Ponatinib | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1271,
25,
1468
]
],
[
[
1271,
24,
1230
],
[
1230,
24,
1468
]
],
[
[
1271,
24,
41
],
[
41,
63,
1468
]
],
[
[
1271,
25,
4
],
[
4,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levo... |
DB00289 | DB06616 | 847 | 594 | [
"DDInter132",
"DDInter224"
] | Atomoxetine | Bosutinib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
847,
24,
594
]
],
[
[
847,
24,
883
],
[
883,
1,
594
]
],
[
[
847,
6,
8374
],
[
8374,
45,
594
]
],
[
[
847,
21,
29231
],
[
29231,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Atomoxetine (Compound) causes Cardiac disorder (Side Effect) and Car... |
DB00059 | DB06186 | 1,560 | 1,439 | [
"DDInter1404",
"DDInter969"
] | Pegaspargase | Ipilimumab | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
1560,
24,
1439
]
],
[
[
1560,
24,
617
],
[
617,
24,
1439
]
],
[
[
1560,
63,
268
],
[
268,
24,
1439
]
],
[
[
1560,
24,
1627
],
[
1627,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alf... |
DB00014 | DB01015 | 521 | 1,247 | [
"DDInter839",
"DDInter1724"
] | Goserelin | Sulfamethoxazole | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
521,
23,
1247
]
],
[
[
521,
21,
28709
],
[
28709,
60,
1247
]
],
[
[
521,
25,
11
],
[
11,
23,
1247
]
],
[
[
521,
24,
688
],
[
688,
... | [
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (... | Goserelin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Sulfamethoxazole (Compound)
Goserelin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Su... |
DB00252 | DB00643 | 362 | 1,370 | [
"DDInter1460",
"DDInter1128"
] | Phenytoin | Mebendazole | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem] | Moderate | 1 | [
[
[
362,
24,
1370
]
],
[
[
362,
24,
510
],
[
510,
1,
1370
]
],
[
[
362,
6,
4973
],
[
4973,
45,
1370
]
],
[
[
362,
7,
10670
],
[
10670,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mebendazole"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Albendazole and Albendazole (Compound) resembles Mebendazole (Compound)
Phenytoin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mebendazole (Compound)
Phenytoin (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) i... |
DB00373 | DB01168 | 461 | 1,053 | [
"DDInter1809",
"DDInter1526"
] | Timolol | Procarbazine | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
461,
24,
1053
]
],
[
[
461,
24,
848
],
[
848,
40,
1053
]
],
[
[
461,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
461,
23,
126
],
[
126,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Timolol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Timolol may cause a minor interaction that can lim... |
DB06273 | DB06372 | 980 | 259 | [
"DDInter1824",
"DDInter1594"
] | Tocilizumab | Rilonacept | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Major | 2 | [
[
[
980,
25,
259
]
],
[
[
980,
23,
1114
],
[
1114,
62,
259
]
],
[
[
980,
62,
1461
],
[
1461,
23,
259
]
],
[
[
980,
63,
1565
],
[
1565,
... | [
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sul... | Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin... |
DB00582 | DB11057 | 1,622 | 720 | [
"DDInter1946",
"DDInter1223"
] | Voriconazole | Mineral oil | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1622,
24,
720
]
],
[
[
1622,
25,
927
],
[
927,
63,
720
]
],
[
[
1622,
25,
175
],
[
175,
24,
720
]
],
[
[
1622,
24,
1151
],
[
1151,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Enco... | Voriconazole may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Voriconazole may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a ... |
DB00531 | DB06168 | 450 | 1,531 | [
"DDInter456",
"DDInter281"
] | Cyclophosphamide | Canakinumab | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
450,
24,
1531
]
],
[
[
450,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
450,
63,
377
],
[
377,
24,
1531
]
],
[
[
450,
24,
1270
],
[
1270,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin an... |
DB00819 | DB00992 | 471 | 842 | [
"DDInter15",
"DDInter1182"
] | Acetazolamide | Methyl aminolevulinate (topical) | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
471,
24,
842
]
],
[
[
471,
21,
28701
],
[
28701,
60,
842
]
],
[
[
471,
25,
213
],
[
213,
36,
842
]
],
[
[
471,
21,
28701
],
[
28701,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Acetazolamide (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Methyl aminolevulinate (Compound)
Acetazolamide may lead to a major life threatening interaction when ta... |
DB06603 | DB08820 | 39 | 1,478 | [
"DDInter1387",
"DDInter997"
] | Panobinostat | Ivacaftor | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
39,
24,
1478
]
],
[
[
39,
63,
307
],
[
307,
23,
1478
]
],
[
[
39,
64,
318
],
[
318,
23,
1478
]
],
[
[
39,
62,
479
],
[
479,
23,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Panobinostat may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cau... |
DB00754 | DB08870 | 157 | 850 | [
"DDInter696",
"DDInter228"
] | Ethotoin | Brentuximab vedotin | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
157,
24,
850
]
],
[
[
157,
63,
267
],
[
267,
24,
850
]
],
[
[
157,
24,
50
],
[
50,
24,
850
]
],
[
[
157,
24,
270
],
[
270,
63,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine an... |
DB00582 | DB08870 | 1,622 | 850 | [
"DDInter1946",
"DDInter228"
] | Voriconazole | Brentuximab vedotin | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1622,
24,
850
]
],
[
[
1622,
24,
896
],
[
896,
24,
850
]
],
[
[
1622,
24,
1033
],
[
1033,
63,
850
]
],
[
[
1622,
64,
134
],
[
134,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib ... |
DB00220 | DB00331 | 798 | 1,645 | [
"DDInter1276",
"DDInter1164"
] | Nelfinavir | Metformin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Moderate | 1 | [
[
[
798,
24,
1645
]
],
[
[
798,
6,
10715
],
[
10715,
45,
1645
]
],
[
[
798,
7,
6104
],
[
6104,
46,
1645
]
],
[
[
798,
18,
5833
],
[
5833,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"SLC22A1"
],
[
"SLC22A1",
"{u} (Gene) is bound by {v} (Compound)"... | Nelfinavir (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Metformin (Compound)
Nelfinavir (Compound) upregulates COPB2 (Gene) and COPB2 (Gene) is upregulated by Metformin (Compound)
Nelfinavir (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Metformin (Compound)
Nelfinavir (Com... |
DB00341 | DB05381 | 1,242 | 172 | [
"DDInter343",
"DDInter863"
] | Cetirizine | Histamine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
1242,
24,
172
]
],
[
[
1242,
24,
1264
],
[
1264,
24,
172
]
],
[
[
1242,
24,
337
],
[
337,
63,
172
]
],
[
[
1242,
35,
252
],
[
252,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenylt... |
DB00065 | DB04845 | 581 | 309 | [
"DDInter923",
"DDInter1001"
] | Infliximab | Ixabepilone | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Major | 2 | [
[
[
581,
25,
309
]
],
[
[
581,
25,
60
],
[
60,
23,
309
]
],
[
[
581,
25,
1419
],
[
1419,
24,
309
]
],
[
[
581,
25,
1619
],
[
1619,
6... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixabepilone"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"... | Infliximab may lead to a major life threatening interaction when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Infliximab may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate inter... |
DB00563 | DB01076 | 663 | 700 | [
"DDInter1174",
"DDInter133"
] | Methotrexate | Atorvastatin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
663,
24,
700
]
],
[
[
663,
24,
788
],
[
788,
1,
700
]
],
[
[
663,
6,
13478
],
[
13478,
45,
700
]
],
[
[
663,
7,
2903
],
[
2903,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Methotrexate (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Atorvastatin (Compound)
Methotrexate (Compound) upregulates MMP1 (Gene) and ... |
DB00202 | DB12267 | 190 | 1,476 | [
"DDInter1716",
"DDInter233"
] | Succinylcholine | Brigatinib | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
190,
24,
1476
]
],
[
[
190,
23,
613
],
[
613,
24,
1476
]
],
[
[
190,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
190,
24,
1011
],
[
1011,
... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Succinylcholine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Irinotecan"
],
... | Succinylcholine may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and... |
DB00081 | DB00775 | 273 | 1,226 | [
"DDInter1838",
"DDInter1818"
] | Tositumomab | Tirofiban | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Major | 2 | [
[
[
273,
25,
1226
]
],
[
[
273,
23,
539
],
[
539,
62,
1226
]
],
[
[
273,
25,
714
],
[
714,
63,
1226
]
],
[
[
273,
24,
529
],
[
529,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tirofiban"
]
],
[
[
"Tositumomab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Tirofiban
Tositumomab may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate ... |
DB00912 | DB01299 | 473 | 698 | [
"DDInter1581",
"DDInter1722"
] | Repaglinide | Sulfadoxine | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
473,
24,
698
]
],
[
[
473,
24,
1247
],
[
1247,
40,
698
]
],
[
[
473,
63,
1029
],
[
1029,
40,
698
]
],
[
[
473,
63,
161
],
[
161,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles S... |
DB01087 | DB01227 | 1,520 | 1,301 | [
"DDInter1520",
"DDInter1043"
] | Primaquine | Levacetylmethadol | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
1520,
25,
1301
]
],
[
[
1520,
64,
494
],
[
494,
1,
1301
]
],
[
[
1520,
63,
675
],
[
675,
1,
1301
]
],
[
[
1520,
6,
8374
],
[
8374,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
... | Primaquine may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylm... |
DB01197 | DB08870 | 1,603 | 850 | [
"DDInter292",
"DDInter228"
] | Captopril | Brentuximab vedotin | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1603,
24,
850
]
],
[
[
1603,
63,
267
],
[
267,
24,
850
]
],
[
[
1603,
24,
1344
],
[
1344,
63,
850
]
],
[
[
1603,
24,
549
],
[
549,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin ... |
DB00501 | DB00559 | 752 | 152 | [
"DDInter380",
"DDInter223"
] | Cimetidine | Bosentan | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
752,
24,
152
]
],
[
[
752,
6,
6017
],
[
6017,
45,
152
]
],
[
[
752,
21,
28778
],
[
28778,
60,
152
]
],
[
[
752,
63,
608
],
[
608,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Cimetidine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Bosentan (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lidoc... |
DB00860 | DB01170 | 891 | 1,150 | [
"DDInter1513",
"DDInter846"
] | Prednisolone | Guanethidine | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
891,
24,
1150
]
],
[
[
891,
6,
8374
],
[
8374,
45,
1150
]
],
[
[
891,
24,
1344
],
[
1344,
63,
1150
]
],
[
[
891,
1,
617
],
[
617,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Prednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanethidine (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Pred... |
DB00321 | DB08899 | 21 | 129 | [
"DDInter78",
"DDInter649"
] | Amitriptyline | Enzalutamide | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
21,
24,
129
]
],
[
[
21,
24,
918
],
[
918,
1,
129
]
],
[
[
21,
6,
8374
],
[
8374,
45,
129
]
],
[
[
21,
21,
28703
],
[
28703,
60,... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Amitriptyline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Amitriptyline (Compound) causes Pruritus (Side Effec... |
DB00682 | DB01166 | 126 | 477 | [
"DDInter1951",
"DDInter379"
] | Warfarin | Cilostazol | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Minor | 0 | [
[
[
126,
23,
477
]
],
[
[
126,
6,
8374
],
[
8374,
45,
477
]
],
[
[
126,
23,
801
],
[
801,
62,
477
]
],
[
[
126,
25,
112
],
[
112,
23... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Brivaracetam and Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Warfarin may lead to a... |
DB00450 | DB11057 | 78 | 720 | [
"DDInter603",
"DDInter1223"
] | Droperidol | Mineral oil | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
78,
24,
720
]
],
[
[
78,
25,
927
],
[
927,
63,
720
]
],
[
[
78,
25,
1151
],
[
1151,
24,
720
]
],
[
[
78,
64,
79
],
[
79,
24,
... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafe... | Droperidol may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Droperidol may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate int... |
DB00374 | DB05812 | 1,061 | 1,374 | [
"DDInter1852",
"DDInter8"
] | Treprostinil | Abiraterone | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1061,
24,
1374
]
],
[
[
1061,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1061,
24,
851
],
[
851,
23,
1374
]
],
[
[
1061,
63,
1028
],
[
10... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Treprostinil",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokalaemia"
],
[
"Hypokalaemia",
"{u} (Side Effe... | Treprostinil (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a minor interaction that can limit clinical effects when taken wit... |
DB05294 | DB11642 | 1,069 | 938 | [
"DDInter1917",
"DDInter1480"
] | Vandetanib | Pitolisant | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Major | 2 | [
[
[
1069,
25,
938
]
],
[
[
1069,
62,
112
],
[
112,
23,
938
]
],
[
[
1069,
24,
28
],
[
28,
24,
938
]
],
[
[
1069,
64,
600
],
[
600,
2... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisac... |
DB00980 | DB11979 | 969 | 1,320 | [
"DDInter1564",
"DDInter625"
] | Ramelteon | Elagolix | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
969,
24,
1320
]
],
[
[
969,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
969,
63,
1051
],
[
1051,
24,
1320
]
],
[
[
969,
24,
159
],
[
159,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and... |
DB01599 | DB11978 | 1,232 | 124 | [
"DDInter1523",
"DDInter822"
] | Probucol | Glasdegib | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1232,
24,
124
]
],
[
[
1232,
62,
112
],
[
112,
23,
124
]
],
[
[
1232,
63,
79
],
[
79,
24,
124
]
],
[
[
1232,
24,
1342
],
[
1342,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib ... |
DB01222 | DB06717 | 617 | 875 | [
"DDInter246",
"DDInter778"
] | Budesonide | Fosaprepitant | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
617,
24,
875
]
],
[
[
617,
63,
723
],
[
723,
1,
875
]
],
[
[
617,
21,
29180
],
[
29180,
60,
875
]
],
[
[
617,
25,
760
],
[
760,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Budesonide (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Budesonide may l... |
DB00264 | DB01284 | 88 | 1,042 | [
"DDInter1200",
"DDInter1782"
] | Metoprolol | Tetracosactide | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
88,
24,
1042
]
],
[
[
88,
24,
455
],
[
455,
23,
1042
]
],
[
[
88,
24,
659
],
[
659,
62,
1042
]
],
[
[
88,
24,
1144
],
[
1144,
24... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vila... |
DB06176 | DB11978 | 1,342 | 124 | [
"DDInter1616",
"DDInter822"
] | Romidepsin | Glasdegib | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1342,
24,
124
]
],
[
[
1342,
62,
1247
],
[
1247,
23,
124
]
],
[
[
1342,
24,
327
],
[
327,
24,
124
]
],
[
[
1342,
24,
1032
],
[
1032,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Romidepsin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[... | Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and... |
DB00889 | DB11986 | 1,133 | 484 | [
"DDInter840",
"DDInter648"
] | Granisetron | Entrectinib | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1133,
24,
484
]
],
[
[
1133,
23,
1247
],
[
1247,
23,
484
]
],
[
[
1133,
25,
222
],
[
222,
23,
484
]
],
[
[
1133,
24,
1539
],
[
1539,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Granisetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Granisetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Granisetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutrami... |
DB00196 | DB00420 | 600 | 508 | [
"DDInter743",
"DDInter1532"
] | Fluconazole | Promazine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Moderate | 1 | [
[
[
600,
24,
508
]
],
[
[
600,
24,
1264
],
[
1264,
63,
508
]
],
[
[
600,
24,
1630
],
[
1630,
1,
508
]
],
[
[
600,
24,
1236
],
[
1236,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenaz... |
DB00465 | DB06228 | 886 | 792 | [
"DDInter1010",
"DDInter1609"
] | Ketorolac | Rivaroxaban | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
886,
25,
792
]
],
[
[
886,
21,
28703
],
[
28703,
60,
792
]
],
[
[
886,
23,
752
],
[
752,
24,
792
]
],
[
[
886,
24,
738
],
[
738,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ketorolac",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compoun... | Ketorolac (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Ketorolac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
... |
DB00087 | DB00262 | 599 | 552 | [
"DDInter41",
"DDInter302"
] | Alemtuzumab | Carmustine | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Moderate | 1 | [
[
[
599,
24,
552
]
],
[
[
599,
24,
810
],
[
810,
63,
552
]
],
[
[
599,
24,
440
],
[
440,
24,
552
]
],
[
[
599,
63,
305
],
[
305,
24,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Carmustine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when ta... |
DB09054 | DB11613 | 384 | 1,519 | [
"DDInter905",
"DDInter1924"
] | Idelalisib | Velpatasvir | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
384,
24,
1519
]
],
[
[
384,
64,
1135
],
[
1135,
23,
1519
]
],
[
[
384,
63,
1374
],
[
1374,
24,
1519
]
],
[
[
384,
64,
594
],
[
594,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol"... | Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Velpatasvir
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a... |
DB00519 | DB06715 | 1,638 | 239 | [
"DDInter1843",
"DDInter1500"
] | Trandolapril | Potassium Iodide | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Major | 2 | [
[
[
1638,
25,
239
]
],
[
[
1638,
21,
29196
],
[
29196,
60,
239
]
],
[
[
1638,
24,
1274
],
[
1274,
24,
239
]
],
[
[
1638,
1,
954
],
[
954,
... | [
[
[
"Trandolapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Trandolapril",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is cau... | Trandolapril (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases whe... |
DB01020 | DB01240 | 1,107 | 885 | [
"DDInter990",
"DDInter657"
] | Isosorbide mononitrate | Epoprostenol | Isosorbide mononitrate is an organic nitrate with vasodilating properties. It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload.[L11698, L11743] Isosorbide mononitrate is an active metabolite of [isosorbide dinitrate]. Li... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1107,
24,
885
]
],
[
[
1107,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1107,
54,
19134
],
[
19134,
15,
885
]
],
[
[
1107,
21,
28684
],
[
286... | [
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"T... | Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Isosorbide mononitrate (Compound) is included by Vasodilation (Pharmacologic Class) and Vasodilation (Pharmacologic Class) includes Epoprosten... |
DB01072 | DB09074 | 915 | 1,362 | [
"DDInter129",
"DDInter1327"
] | Atazanavir | Olaparib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
915,
25,
1362
]
],
[
[
915,
63,
2
],
[
2,
24,
1362
]
],
[
[
915,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
915,
62,
1684
],
[
1684,
... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
],
[
"Alosetron",
... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Atazanavir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a mode... |
DB00500 | DB13620 | 24 | 948 | [
"DDInter1831",
"DDInter1499"
] | Tolmetin | Potassium gluconate | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Moderate | 1 | [
[
[
24,
24,
948
]
],
[
[
24,
24,
848
],
[
848,
24,
948
]
],
[
[
24,
1,
831
],
[
831,
24,
948
]
],
[
[
24,
40,
886
],
[
886,
24,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Tolmetin (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction tha... |
DB00991 | DB09054 | 97 | 384 | [
"DDInter1358",
"DDInter905"
] | Oxaprozin | Idelalisib | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
97,
24,
384
]
],
[
[
97,
24,
222
],
[
222,
23,
384
]
],
[
[
97,
40,
307
],
[
307,
23,
384
]
],
[
[
97,
25,
1618
],
[
1618,
24,
... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Oxaprozin (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit cl... |
DB00791 | DB08904 | 132 | 375 | [
"DDInter1902",
"DDInter342"
] | Uracil mustard | Certolizumab pegol | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
132,
25,
375
]
],
[
[
132,
63,
1461
],
[
1461,
23,
375
]
],
[
[
132,
24,
1367
],
[
1367,
63,
375
]
],
[
[
132,
24,
1430
],
[
1430,
... | [
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis... |
DB00489 | DB01069 | 17 | 401 | [
"DDInter1704",
"DDInter1533"
] | Sotalol | Promethazine | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Major | 2 | [
[
[
17,
25,
401
]
],
[
[
17,
25,
1264
],
[
1264,
63,
401
]
],
[
[
17,
24,
1376
],
[
1376,
63,
401
]
],
[
[
17,
24,
104
],
[
104,
24,... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a... | Sotalol may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause ... |
DB00087 | DB08889 | 599 | 350 | [
"DDInter41",
"DDInter299"
] | Alemtuzumab | Carfilzomib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
599,
24,
350
]
],
[
[
599,
24,
1270
],
[
1270,
63,
350
]
],
[
[
599,
24,
482
],
[
482,
24,
350
]
],
[
[
599,
63,
1253
],
[
1253,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified prot... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Alemtuzumab may cause a moderate interaction that coul... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.